Q BioMed plans for clinical testing with its autism drug QBM-001

Q BioMed Inc (OTCQB: QBIO) CEO Denis Corin tells Proactive Investors’ Christine Corrado the biomedical acceleration and development company is in the middle of preparing for the planned clinical trial of its drug candidate QBM-001, which is being tested to treat pediatric developmental nonverbal disorder in toddlers who suffer

Read the full article at the original source

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.